MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - October 16, 2012) - MorphoSys AG /
AbD Serotec Licenses HuCAL Antibodies to DiaSorin for Use in Clinical
Diagnostic
Assays for Infectious Disease Testing. Processed and transmitted by Thomson
Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
that
DiaSorin S.p.A., a worldwide provider of specialty assays, has taken a
license
for two recombinant HuCAL antibodies. The antibodies, which were made
by AbD
Serotec, MorphoSys's division for research and diagnostic antibodies,
act as
recombinant controls for two marketed infectious disease assays. AbD
Serotec
will receive license fees and royalties on sales of kits
comprising the
antibodies. Further financial details were not disclosed.
The collaboration between DiaSorin and AbD Serotec brings together
DiaSorin's
broad expertise in the development, manufacturing and
marketing of
immunodiagnostic test systems and AbD Serotec's leading recombinant
HuCAL
antibody generation technology. AbD Serotec has generated two
recombinant
antibodies in the IgM format, which DiaSorin is implementing into
its new
diagnostic tests for Measles IgM and Mumps IgM. The introduction of the
DiaSorin
LIAISON® Measles IgM and LIAISON® Mumps IgM assays provides
the first and
only fully automated immunoassays on the diagnostic market for the
serological
determination of the immunity status of patients to measles and mumps
viruses.
"Today's news is another example of AbD Serotec's ability to offer
superior
solutions for diagnostic companies in the quickest possible time using the
HuCAL
technology", commented Dieter Feger, Senior Vice President and
Head of
MorphoSys's AbD Serotec Division. "Recombinant control antibodies based
on our
HuCAL technology support the provision of accurate results through
effective
diagnostic assay management."
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library
technology in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of
therapeutic
antibodies, one of the fastest-growing drug classes in human
healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody
technologies to
generate superior monoclonal antibodies for research and
diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic
pipeline of more than 70 human antibody drug candidates for the
treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With
its ongoing commitment to new antibody technology and drug
development,
MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®
and Ylanthia® and 100 billion high potentials® are registered
trademarks of
MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology
GmbH, a
subsidiary of MorphoSys AG.
LIAISON® is a registered trademark of DiaSorin S.p.A.
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.
Media Release (PDF):
http://hugin.info/130295/R/1649194/531777.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1649194]
